Matt Troyer

Matt Troyer leads the Early Clinical function and is responsible for overseeing a team of physician-scientists who execute Denali’s early clinical programs. The Early Clinical group partners with pre-clinical teams, including Translational and Development Sciences, to design and conduct first-in-human, biomarker, experimental medicine and other early studies in healthy subjects and patients. Matt and the Early Clinical team execute the first clinical investigations that drive Denali’s biomarker-driven development strategy.

Matt is a neurologist with subspecialty training in Parkinson’s disease and Movement Disorders and 14 years of early clinical leadership. Matt previously led early development programs at Medivation and at Merck & Co., Inc. where he was Executive Director and Neuroscience Therapeutic Area lead for Early Clinical Development, with responsibility for pre-clinical to proof-of-concept programs in Alzheimer’s disease, Parkinson’s disease, sleep disorders, pain, migraine, schizophrenia and other CNS indications.

Matt completed neurology residency training at Harvard Medical School in the Longwood Area Program and completed a fellowship in Parkinson’s disease and Movement disorders at the Institute of Neurology, Queen Square, London. Following his clinical fellowship, Matt did a postdoctoral research fellowship in the laboratory of Robert Edwards at UCSF, focusing on basic mechanisms of presynaptic function and Parkinson’s disease. Matt subsequently joined the Neurology faculty at UCSF with both clinical and research responsibilities. Matt received his M.D. from Stanford University and a B.A. in biology from Illinois Wesleyan University.